Isentress
developed to target human immunodeficiency virus infection to alleviate viral load.
Strengths: 400mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Zepdon
- Therapeutic class
Integrase Inhibitor
- Pharmacological class
HIV-1 Integrase Strand Transfer Inhibitor
- Contraindications
hypersensitivity to raltegravir
- Minor side effects
headache; nausea; diarrhoea; insomnia
- Moderate side effects
abdominal pain; elevated liver enzymes
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Merck Sharp & Dohme
- Onset Time
1–4 hours
- Duration
12 hours
- Storage instructions
Store below 30°C in the original packaging.
- Drug interactions
Rifampicin; St. John's Wort
- Age restrictions
Dosage adjusted based on weight and age.
Precautions and warnings
monitor for symptoms of immune reconstitution syndrome; use with caution in patients with hepatic impairment
Serious side effects
rhabdomyolysis — requires immediate medical attention; severe skin reactions — requires immediate medical attention; myopathy — requires immediate medical attention
Patient summary
developed to target human immunodeficiency virus infection to alleviate viral load.
Mechanism of action
This medicine acts as an integrase strand transfer inhibitor, blocking the enzyme that the virus requires to replicate and integrate its genetic material into the host cell DNA.
Pregnancy and breastfeeding
Pregnancy: use only if potential benefit justifies potential risk. Breastfeeding: breastfeeding is generally not recommended for HIV positive mothers.
Isentress
developed to target human immunodeficiency virus infection to alleviate viral load.
Editorial Notes
- Active ingredient(s): Raltegravir
- Listed indication(s): HIV Infection
Available option
- 60 tablets - 400 mg1481-400-mg-17498